ライフサイエンスコーパス: specific disease

1 PTCL was not pathognomonic for any specific disease.

2 suggesting a link between systemic and site-specific disease.

3 ubiquitously expressed genes lead to retina-specific disease.

4 ery method to identify panels of markers for specific disease.

5 ion of multiple biomarkers associated with a specific disease.

6 no convincing direct causal relation to any specific disease.

7 evelopment as opposed to being assigned to a specific disease.

8 nction, and proposed that JNCL is a mutation-specific disease.

9 lamin A and emerin cause cardiac- or muscle-specific disease.

10 iven to randomized controlled trials of site-specific disease.

11 n no genes are known to be associated with a specific disease.

12 ly assess the value of an intervention for a specific disease.

13 expressed RNA-binding proteins cause tissue specific disease.

14 pes often does not explain the etiology of a specific disease.

15 he microbiome rather than connections with a specific disease.

16 or the adaptation of pathway signatures into specific disease.

17 spasticity, and dystonia, hallmarks of brain-specific disease.

18 ubiquitously expressed DYNC1H1 cause neuron-specific disease.

19 entify targets that may be associated with a specific disease.

20 with these procedures can be associated with specific diseases.

21 position and its correlation with health and specific diseases.

22 fluenced by age, gender, and the presence of specific diseases.

23 que predictions concerning the etiologies of specific diseases.

24 f known cases of small molecules that target specific diseases.

25 mutations in NPC components result in tissue-specific diseases.

26 for stratifying individual risk profiles in specific diseases.

27 cept of importance in vaccine design against specific diseases.

28 relapsing-remitting EAE and other SJL strain-specific diseases.

29 predisposition to more than 80 human tissue-specific diseases.

30 rofiling of BRCA1 or other genes relevant to specific diseases.

31 oups to distinguish their individual role in specific diseases.

32 therapies targeting the relevant isoform for specific diseases.

33 male offspring but little is known regarding specific diseases.

34 pressed in the kidney and are upregulated in specific diseases.

35 claimed to treat, prevent, diagnose, or cure specific diseases.

36 not make claims for the treatment or cure of specific diseases.

37 ique molecules for an autoimmune response in specific diseases.

38 development, and the possible occurrence of specific diseases.

39 of more than 70 human genes associated with specific diseases.

40 t pathogens, label cells/tissues, and report specific diseases.

41 associated with developmental syndromes and specific diseases.

42 rs, or different ones, of relevance to other specific diseases.

43 tic testing, contributes to the detection of specific diseases.

44 as a potential strategy to treat prelamin A-specific diseases.

45 ty landscape that have potential relation to specific diseases.

46 f the maturation system, are associated with specific diseases.

47 values of quantitative traits or those with specific diseases.

48 se treatments into management strategies for specific diseases.

49 between anti-Jo-1 antibody levels and organ-specific disease activity in cross-sectional and longitu

50 nnaire (HAQ) score collected, and had the RA-specific Disease Activity Score performed by a rheumatol

51 ance status, and clinical remission of organ-specific disease after this form of treatment.

52 Characterization of population-specific disease alleles may have important implications

53 nsSNPs among multiple genes associated with specific diseases, anatomies, mammalian phenotypes, gene

54 ay be a critical mediator of inflammation in specific disease and injury states, potentially by promo

55 nds beyond episodes of illness or care for a specific disease and is ongoing over time.

56 on prior methods and can suggest markers for specific disease and response stages that are not found

57 y associated changes that help predispose to specific diseases and also identifies novel windows of p

58 l toxicant that causes a wide range of organ-specific diseases and cancers.

59 thylation patterns have been associated with specific diseases and environmental exposures, the media

60 we highlight some of these diverse and site-specific diseases and how they fit the DRF classificatio

61 ency, enhancing the diagnostic precision for specific diseases and reducing diagnostic cost.

62 variations that may affect susceptibility to specific diseases and that influence the pharmacokinetic

63 less is known about the end-of-life costs of specific diseases and the associated financial risk for

64 pact on how genetic variation contributes to specific diseases and traits by providing a compendium o

65 alpha2-Glia(63-71)-NH2, was able to identify specific disease antibodies with a sensitivity of 50% an

66 Specific diseases are definable, but mechanisms are poor

67 dual-acting modulator opportunities within a specific disease area.

68 o develop enhanced ability and experience in specific disease areas or procedures will benefit patien

69 in-responsive megaloblastic anemia, a tissue-specific disease associated with diabetes mellitus, mega

70 Specific diseases associated with fecal incontinence inc

71 nt advances in nanomedicines that can target specific disease-associated cells.

72 ctivity and often-observed overexpression of specific disease-associated enzymes make them extremely

73 lysis of PDAC patient samples has shown that specific disease-associated mutations are correlated wit

74 tructures, perhaps each corresponding to the specific disease-associated protein with distinct conseq

75 To prioritize lineage-specific, disease-associated lncRNA expression, we emplo

76 igning clinical trials and assessing malaria-specific disease associations.

77 We compared rates of serotype-specific disease before and after PCV7 was licensed for

78 ned antibodies are used for the detection of specific disease biomarker proteins in buffer and in com

79 tal stage of life exacerbated not only organ-specific diseases but also systemic autoimmune diseases.

80 enes and processes that predispose organs to specific diseases can be identified using gene expressio

81 ity to cure and prevent disease, to identify specific disease causes (microbes), and to deal with div

82 tential for targeted therapy directed at the specific disease-causing abnormality.

83 To understand pathophysiology, the specific disease-causing gene(s) within each CNV need to

84 ructs for gene therapy) that are tailored to specific disease-causing mutants of CFTR.

85 with the creation and inclusion of pediatric-specific disease characteristics in the most recent WHO

86 little systematic evaluation of the species-specific disease characteristics.

87 Incorporating race-specific disease comorbidity patterns will produce a mor

88 on our understanding of the pathogenesis of specific disease conditions after renal transplantation,

89 ing where related actions of CLA converge in specific disease conditions and physiologic states is ho

90 anatomy, neurophysiology, pathophysiology in specific disease conditions, autonomic testing, risk str

91 es and sub-cellular locations, perhaps under specific disease conditions.

92 species (HAdV-A to -G), each associated with specific disease conditions.

93 Because of cancer's high symptom burden and specific disease course, patients with cancer are more l

94 In the context of cancer, tumours may have specific disease-defining mutations, but a patient's ger

95 oducts can treat, prevent, diagnose, or cure specific diseases, despite regulations prohibiting such

96 nly 14.6% of the patients did never have any specific disease diagnosed before graft loss.

97 body areas, is a clinical sign rather than a specific disease diagnosis.

98 ntives and mortality needs to be assessed in specific disease domains.

99 of prematurity, but rather caused by either specific disease during intensive care or factors operat

100 Although fish consumption may reduce specific disease endpoints, such as sudden cardiac death

101 m of platelet microparticle participation in specific disease entities such as rheumatoid arthritis h

102 redict left ventricular filling pressures in specific disease entities.

103 e following five pathogenic types, each with specific disease entities: immune-complex GN, pauci-immu

104 sillar cancer in particular is emerging as a specific disease entity with distinct molecular, patholo

105 opportunities, perceived needs and barriers, specific disease examples, and recommendations on facili

106 teins the active MMP forms important for the specific disease for identification.

107 The actuarial 5-year overall, disease-specific, disease-free, and distant metastasis-free surv

108 Of the specific diseases, FSGS and MGN recurred more commonly (

109 ranscriptomes and may represent novel muscle-specific disease genes.

110 ions were concentrated and associated with a specific disease group.

111 Chronic histological damage and specific diseases had additive and independent impact on

112 s shown to harbor HTLV-2 in association with specific diseases has, to date, precluded convincing epi

113 r of quantitative epidemiological studies of specific diseases have been done in developing countries

114 idence of upper and lower GIB related to age-specific disease, higher burden of comorbidity and incre

115 h HD has historically been viewed as a brain-specific disease, htt is expressed ubiquitously, and rec

116 n by the observers to that expected for each specific disease in the study group on the basis of repo

117 Moreover, genes associated with specific diseases in humans are also found in flies, som

118 and their relationship to decreased risk of specific diseases in infants.

119 ells offer a new way to recapitulate patient specific diseases in vitro, providing an almost limitles

120 me and may ultimately be useful for treating specific diseases in which PAD2 activity is dysregulated

121 Age group-specific disease incidence rates and abridged life table

122 lamins, are associated with multiple tissue-specific diseases, including Emery-Dreifuss (EDMD2/3) an

123 t to understanding ill health as a result of specific diseases, increasingly defined more by signs th

124 covers current hypotheses regarding antigen-specific disease induction, immune responses within the

125 nitratively modified with tissue injury in a specific disease is limited, however.

126 he allergy field is to understand how tissue-specific disease is manifested.

127 of interest, such as those correlating to a specific disease, is critical when analysing flow cytome

128 been extended by prevention and treatment of specific diseases, life span can be altered by modifying

129 many examples of novel and African ancestry-specific disease loci that have been discovered.

130 nic cells contribute to both generalized and specific disease manifestations.

131 tween cells in mosaic females lead to female-specific disease manifestations.

132 e genetic effects that influence the risk of specific disease manifestations.

133 ulties in provision of appropriate drugs for specific diseases, many other factors contribute to the

134 onses has not been possible due to lack of a specific disease marker.

135 cardiomyocytes to gain insights into patient-specific disease mechanism and pharmacotherapy.

136 ation of miRNAs in HF, shedding light on the specific disease mechanisms differentiating diabetic pat

137 Specific disease mechanisms implicated in childhood arte

138 ropathy, has raised many questions about the specific disease mechanisms involved.

139 treatments through improved understanding of specific disease mechanisms.

140 these mice may arise through multiple tissue-specific disease mechanisms.

141 Biopharmaceuticals that target specific disease-mediating molecules have advanced our u

142 s been proposed, but the nature of such site-specific disease memory is unknown.

143 Survival and time from diagnosis to specific disease milestones were calculated to assess di

144 ting complex signal integration in a patient-specific disease milieu.

145 d specific cell types is crucial for patient-specific disease modeling and drug testing.

146 nsplantation, drug toxicity testing, patient-specific disease modeling, and even ex vivo gene therapy

147 y testing, cell transplantation, and patient-specific disease modeling.

148 f somatic gene transfer in creating genotype-specific disease models.

149 tro and used to generate patient- and tissue-specific disease models.

150 s, suggesting that these two factors are sex-specific disease modifiers and raising the possibility t

151 ients with rheumatoid arthritis (RA) in whom specific disease-modifying antirheumatic drugs (DMARDs)

152 evelopment of novel therapeutics, and target specific disease-modifying pathways intrinsic to the ven

153 ing of neurodegenerative diseases increases, specific disease-modifying treatments might become avail

154 hate receptor 2 (S1PR2) as a sex- and strain-specific, disease-modifying molecule that regulates BBB

155 kely reflects the cellular source of IL-6 in specific diseases, much of which may be produced by nonh

156 elevated in mice prone to Th1-mediated organ-specific disease (nonobese diabetic (NOD) and SJL mice)

157 nformation presented is further organized by specific diseases now associated with the microbiota: St

158 But how is a joint-specific disease of autoimmune and inflammatory nature i

159 Glaucoma is a specific disease of the optic nerve and is often more se

160 d be implemented in treatment algorithms for specific diseases of kidney allografts.

161 in estimating the probability or risk that a specific disease or condition is present (diagnostic mod

162 The primary outcome measure was specific disease or diseases stratified by HIV status.

163 ses, which are often specialized to target a specific disease or host organism.

164 Health problems were not focused on specific diseases or limited to survivors with readily i

165 y postreceptor signal regulators involved in specific diseases or organ adaptation, we used an expres

166 logical processes or therapeutic targets for specific diseases or patient types.

167 Most are voluntary and may be organ specific, disease or condition specific, organ and disea

168 HTLV-I infection may modify the risk of specific disease outcomes by altering host immune functi

169 ication of tumour sub-populations that drive specific disease pathologies for the development of ther

170 sera can be used to understand the pregnancy-specific disease pathology in mice and can predict the d

171 proven mechanisms of action interfering with specific disease pathways, and approaches that could be

172 sary for glucose homeostasis, resulting in a specific disease pattern linking chromatin modification

173 first evidence for a relationship between a specific disease phenotype and a specific structural dom

174 Despite these changes, the 263K strain-specific disease phenotype was preserved after passage t

175 ificant function and that JNCL is a mutation-specific disease phenotype.

176 ein domain specificity direct cells toward a specific disease phenotype.

177 evaluated in human blood cells expressing a specific disease phenotype.

178 isease characteristics, molecular markers of specific disease phenotypes and more efficacious treatme

179 on of exhaled breath metabolites with gender-specific disease phenotypes and pharmacokinetics in the

180 an infections, but the mechanisms leading to specific disease phenotypes can be investigated using st

181 sts caution should be taken when attributing specific disease phenotypes to these repeat lengths.

182 ve analysis of gene matrices associated with specific disease phenotypes, therefore allowing screenin

183 the vast majority of MDS cases and underlie specific disease phenotypes.

184 may play an important role in TMEV subgroup-specific disease phenotypes.

185 OGGs are often associated with specific disease phenotypes.

186 te response pathways corresponding to strain-specific disease phenotypes.

187 or identify early signs of efficacy within a specific disease population.

188 ually lacked power to detect loci with locus-specific disease prevalence/sib-risk ratios (lambda(s))

189 Unless a specific disease process can be identified, what drives

190 screens to identify novel genes involved in specific disease processes and chemical screens to ident

191 omes increasingly sophisticated, focusing on specific disease processes and empirically tested and ef

192 tial measurements of ECM remodeling to these specific disease processes are warranted.

193 tions of NF-kappaB in normal homeostasis and specific disease processes in the intestinal tract.

194 ays not previously identified in the obesity-specific disease profile.

195 more precisely identify correlates of virus-specific disease-protective responses.

196 century, epidemiologists have stratified age-specific disease rates by year of birth to better unders

197 Because they carry specific disease-related RNAs and proteins, practical ap

198 inding protein ASF/SF2 as a critical, allele-specific, disease-relevant effector of cyclin D1b produc

199 nd may open up new opportunities for patient-specific, disease-relevant research.

200 Some trigger the action of specific disease resistance (R) gene products.

201 Nonrace specific disease resistance 1 (NDR1) is a conserved down

202 o study the striking MHC-determined pathogen-specific disease resistance at the molecular level.

203 This siRNA contributes to RPS2-mediated race-specific disease resistance by repressing PPRL, a putati

204 Race-specific disease resistance in plants is mediated by the

205 sts; they are also the proteins that trigger specific disease resistance in resistant plant hosts.

206 Specific disease resistance of Arabidopsis thaliana agai

207 Many race- or isolate-specific disease resistance responses of plants toward p

208 Gene-for-gene type specific disease resistance that is effective against ri

209 rowth identified one mutant, ndr1-1 (nonrace-specific disease resistance), that was susceptible to DC

210 d immunity (ETI) has been implicated in race-specific disease resistance.

211 ffector action, the requirement for NON-RACE-SPECIFIC DISEASE RESISTANCE1 (NDR1) is shared.

212 Arabidopsis (Arabidopsis thaliana) NON-RACE-SPECIFIC DISEASE RESISTANCE1 (NDR1), a plasma membrane-l

213 We propose an adjusted, gender-specific disease risk stratification scheme for Middle E

214 ncidence (hospitalisation or death) rates of specific diseases, RRs were as follows: pulmonary embolu

215 Within this framework, a specific disease's expression is a consequence of the in

216 administration schedule should be focused on specific disease settings, such as breast cancer and int

217 ces in T cell homing could contribute to sex-specific disease severity in this murine model, and also

218 ients with severe sepsis and septic shock in specific disease severity subgroups.

219 earch with population changes in the risk of specific diseases should be analyzed.

220 ability to link each recommended medicine to specific diseases, should allow public officials to appl

221 spond to published mutations associated with specific diseases, some of these differences did result

222 ent sets of M-modules that are important for specific disease stage transitions and offer new insight

223 narrow outcomes such as income, or a single specific disease state, or a measure of positive affect.

224 n such as which genes are overexpressed in a specific disease state.

225 ew information regarding editing patterns in specific disease states and in response to pharmacologic

226 erstanding of NET properties associated with specific disease states and microbial infections.

227 reatment of complement-mediated hemolysis in specific disease states are described.

228 g on children who fulfilled the criteria for specific disease states as defined by the consensus crit

229 of enteral nutrition and their efficacy for specific disease states continue to demonstrate the diff

230 on that accurately and reproducibly identify specific disease states in murine atherosclerosis.

231 iagnostic and therapeutic decision making in specific disease states such as hypertrophic cardiomyopa

232 n detecting pathway networks associated with specific disease states when compared to published pathw

233 ring normal development and are disrupted in specific disease states, particularly in cancer.

234 g the antimicrobial review process to target specific disease states, reassessing the usefulness of c

235 Factors such as patient-specific disease states, resident guideline learning cur

236 costimulatory pathway, they are tailored for specific disease states--abatacept for autoimmune diseas

237 activities in normal cellular processes and specific disease states.

238 ables may also aid in outcome prediction for specific disease states.

239 xpression pattern signatures associated with specific disease states.

240 s may provide new therapeutic approaches for specific disease states.

241 n filament function that results in mutation-specific disease states.

242 litate development of treatments tailored to specific disease subgroups and could potentially enable

243 nd the molecular classification of PDAC into specific disease subtypes have all converged to illumina

244 identifying rational therapeutic targets in specific disease subtypes.

245 explanation for the genetic basis of tissue-specific diseases such as AMD and atypical hemolytic ure

246 olecular imaging followed by applications to specific diseases such as Barrett's esophagus and colon

247 opment of new therapeutic approaches for RPE-specific diseases such as certain forms of retinitis pig

248 transplantation, including studies of human-specific diseases such as hepatitis-C, as treatment for

249 screen all newly arriving migrants for some specific diseases (such as tuberculosis) and can be used

250 restricted populations, or been targeted at specific diseases, such as cancer.

251 issues are infected and contribute to tissue-specific diseases, such as encephalitis and dementia in

252 uture routes to understanding the biology of specific disease susceptibility loci.

253 these measures depend on the recognition of specific disease symptoms, we investigate the relative t

254 the plant's auxin response system to induce specific disease symptoms.

255 Subsequently, specific disease syndromes were discussed in more detail

256 prospects for vaccines that protect against specific disease syndromes.

257 Depending on the specific disease target, there may be one or many cell t

258 s to achieve high levels of drug delivery to specific diseased targets such as tumours.

259 into cardiomyocytes, they model a patient's specific disease, test pharmaceuticals, and potentially

260 later phase trials that assess efficacy in a specific disease that spans adult and pediatric populati

261 ts have evaluated conventional treatments of specific diseases; they are critical but underfunded and

262 me of these diagnoses owe their existence as specific diseases to the norms and practices of an older

263 vity is anticipated and when relevant to the specific disease type.

264 logically meaningful biomarkers related to a specific disease under study.

265 In the remaining 57 patients (28%), no specific disease was found.

266 V following experimental inoculation, but no specific disease was readily apparent from these infecti

267 ting the total number of persons living with specific diseases, we applied prevalence estimates of th

268 temporal pattern and age-dependent nature of specific diseases, we find that smallpox is more consist

269 between distantly related grasses to control specific diseases, we identified a maize R gene that rec

270 model of clinical prevention that focuses on specific diseases, well-defined preventive interventions

271 ct relations between vitamin D(3) status and specific diseases while advocating the safest possible m

272 the top down, focusing on the prevalence of specific diseases within a population.

273 than a single disease, the identification of specific diseases within the syndrome would facilitate t